|This article needs additional citations for verification. (March 2010) (Learn how and when to remove this template message)|
|Traded as||DSE: RENATA|
|Headquarters||Mirpur, Dhaka, Bangladesh|
|South Asia, South East Asia, Africa, Europe and Latin America|
|Syed S Kaiser Kabir (CEO)|
|Products||Ranitidine, Napa, Pretin, Amdocal, Tamona and more|
Number of employees
Renata Limited (formerly Pfizer Laboratories (Bangladesh) Limited), also known as Renata, is one of the top ten (in terms of revenue) pharmaceutical manufacturers in Bangladesh. Renata is engaged in the manufacture and marketing of human pharmaceutical and animal health products. The company also manufactures animal therapeutics and nutrition products. Renata currently employs about 2300 people in its head office in Mirpur, Dhaka and its two production facilities in Mirpur, Dhaka and Rajendrapur, Dhaka.
The company began its operations as Pfizer (Bangladesh) Limited in 1972. For the next two decades it continued as a subsidiary of Pfizer Corporation. However, by the late 1990s the focus of Pfizer had shifted from formulations to research. In accordance with this transformation, Pfizer divested its interests in many countries, including Bangladesh. Specifically, in 1993 Pfizer transferred the ownership of its Bangladesh operations to local shareholders, and the name of the company was changed to Renata Limited.
At present, Renata manufactures about 300 generic pharmaceutical products including hormones, contraceptives, anti-cancer drugs, oral preparations, cephalosporins, parenteral preparations as well as other conventional drugs. In addition, they also offer about 95 animal therapeutics and nutrition products.
Recently, Renata Limited has received the UK MHRA approval for its Potent Product Facility. This facility currently manufactures hormone, steroid and cytotoxic drugs, and is exporting prednisolone to the UK.
The company also operates four other manufacturing units – the original Pfizer facility for general products, a UNICEF-approved SFF (Sachet Filling Facility), a Cephalosporin facility, and a Penicillin facility.
Recently, GAIN (The Global Alliance for Improved Nutrition) provided US$2.9 million to Renata Limited and BRAC, one of the biggest NGOs in the developing world, to build and operate an innovative business model to produce and deliver multi-nutrient powders to vulnerable infants in Bangladesh.
As of the third quarter of 2010, Renata exports its products to the UK, Afghanistan, Cambodia, Hong Kong, the Philippines, Jordan, Sri Lanka, Vietnam, Myanmar, Kenya, Belize, Nepal, Malaysia, and Guyana, with registration ongoing in 23 other countries.
- Haroon, Jasim Uddin (15 February 2010). "Square tops list of 10, Incepta second". The Financial Express. Dhaka. Archived from the original on 1 October 2011.
- "Renata Ltd (RENATA:Dhaka)". Bloomberg Businessweek. Archived from the original on 5 October 2012.
- Chowdhury, Raihan M. (10 November 2007). "Pharmaceutical sector development necessitates vertical integration". The Financial Express. Dhaka.
- Khan, Jasim Uddin (4 June 2008). "Renata set to export medicine to Europe". The Daily Star.